Case Type: Mergers & Acquisitions

Climate Change Crisis Real Impact I Acquisition Corp. (CLII) relating to its proposed merger with EVgo Services LLC. Under the terms of the agreement, CLII will acquire EVgo through a reverse merger, with EVgo emerging as a publicly traded company.

CM Life Sciences, Inc. (CMLF) relating to its proposed merger with Sema4. Under the terms of the agreement, CMLF will acquire Sema4 through a reverse merger, with Sema4 emerging as a publicly traded company.

Forest Road Acquisition Corp. (FRX) relating to its proposed merger with The Beachbody Company Group, LLC. Under the terms of the agreement, FRX will acquire Beachbody through a reverse merger, with Beachbody emerging as a publicly traded company.

ACE Convergence Acquisition Corp. (ACEV) relating to its proposed merger with Achronix Semiconductor Corp. Under the terms of the agreement, ACEV will acquire Achronix through a reverse merger, with Achronix emerging as a publicly traded company.

Decarbonization Plus Acquisition Corp. (DCRB) relating to its proposed merger with Hyzon Motors, Inc. Under the terms of the agreement, DCRB will acquire Hyzon through a reverse merger, with Hyzon emerging as a publicly traded company.

Fusion Acquisition Corp. (FUSE) relating to its proposed merger with MoneyLion, Inc. Under the terms of the agreement, FUSE will acquire MoneyLion through a reverse merger, with MoneyLion emerging as a publicly traded company.

Falcon Capital Acquisition Corp. (FCAC) relating to its proposed merger with Sharecare, Inc. Under the terms of the agreement, FCAC will acquire Sharecare through a reverse merger, with Sharecare emerging as a publicly traded company.

Helix Technologies, Inc. (HLIX) relating to its proposed merger with Medical Outcomes Research Analytics, LLC. Under the terms of the agreement, HLIX shareholders are expected to receive 0.02731 shares of newly-formed company Forian, Inc. per share of HLIX they own.

Synacor, Inc. (SYNC) relating to its proposed acquisition by Centre Lane Partners, LLC. Under the terms of the tender offer, SYNC shareholders are expected to receive $2.20 in cash per share they own.

Viela Bio, Inc. (VIE) relating to its proposed acquisition by Horion Therapeutics plc. Under the terms of the tender offer, VIE shareholders are expected to receive $53.00 per share they own.